Drug Res (Stuttg) 2016; 66(11): 614-616
DOI: 10.1055/s-0042-112366
Short Communication
© Georg Thieme Verlag KG Stuttgart · New York

Agomelatine and Transient Elevation of Creatine Phosphokinase

A. Zormann
1   Department of Psychiatry, University of Basel, Basel, Switzerland
,
J. Blum
1   Department of Psychiatry, University of Basel, Basel, Switzerland
,
C. Suenderhauf
2   Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland
,
M. Vogel
1   Department of Psychiatry, University of Basel, Basel, Switzerland
,
A. Walter
1   Department of Psychiatry, University of Basel, Basel, Switzerland
› Author Affiliations
Further Information

Publication History

received 06 June 2016

accepted 08 July 2016

Publication Date:
09 August 2016 (online)

Preview

Abstract

Agomelatine is an antidepressant drug with moderate agonistic action at the melatonine receptor MT1 and weak effect at MT2. According to clinical studies, agomelatine ameliorates depressive symptoms and improves sleep quality. Side effects such as elevated liver enzymes are well-known. Therefore, routine laboratory monitoring of liver function is recommended periodically throughout treatment because of a rare risk of more serious liver reactions. 2 patients with creatine phosphokinase elevation during treatment with agomelatine are presented. We recommend a check of the creatine phosphokinase level during the initial treatment phase in patients receiving agomelatine for the first time.